Efficacy of injectable platelet-rich fibrin (i-PRF) as a novel vehicle for local drug delivery in non-surgical periodontal pocket therapy: A randomized controlled clinical trial.
{"title":"Efficacy of injectable platelet-rich fibrin (i-PRF) as a novel vehicle for local drug delivery in non-surgical periodontal pocket therapy: A randomized controlled clinical trial.","authors":"Murugan Thamaraiselvan, Nadathur Doraisamy Jayakumar","doi":"10.34172/japid.2024.021","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The vehicle in a local drug delivery (LDD) system plays a vital role in delivering the active drug component at the diseased site. Liquid/injectable platelet-rich fibrin (i-PRF), an autologous fibrin matrix, might be used as a vehicle to enmesh drugs and deliver locally at the periodontally diseased sites. This study evaluated the efficacy of the drug (ciprofloxacin [Cip])-loaded i-PRF as a LDD system adjunct to subgingival debridement in subjects with periodontal pockets.</p><p><strong>Methods: </strong>In a parallel design study, 79 periodontally diseased pocket sites were randomized to 3 groups: group 1 (n=25), scaling and root planing (SRP)+i-PRF+Cip; group 2 (n=25), SRP+i-PRF; group 3 (n=25), SRP without any adjunctive intervention. Clinical parameters (probing depth [PD], clinical attachment level [CAL], gingival index [GI], plaque index [PI]) and microbial quantification (relative quantification of levels of <i>Aggregatibacter actinomycetemcomitans</i>) were assessed from baseline to 6th and 12th weeks of follow-up.</p><p><strong>Results: </strong>All the treatment groups showed significant improvements in the clinical and microbial parameters assessed. Group 1 showed significantly higher PD and GI reduction with CAL gain and decreased in relative levels of <i>A. actinomycetemcomitans</i> in the 12th week, followed by group 2 compared to group 3.</p><p><strong>Conclusion: </strong>Thus, within the limits of this study, it can be concluded that i-PRF could be considered a potential LDD vehicle for the delivery of ciprofloxacin in periodontal pocket therapy.</p>","PeriodicalId":73584,"journal":{"name":"Journal of advanced periodontology & implant dentistry","volume":"16 2","pages":"94-102"},"PeriodicalIF":0.0000,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11699261/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of advanced periodontology & implant dentistry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.34172/japid.2024.021","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: The vehicle in a local drug delivery (LDD) system plays a vital role in delivering the active drug component at the diseased site. Liquid/injectable platelet-rich fibrin (i-PRF), an autologous fibrin matrix, might be used as a vehicle to enmesh drugs and deliver locally at the periodontally diseased sites. This study evaluated the efficacy of the drug (ciprofloxacin [Cip])-loaded i-PRF as a LDD system adjunct to subgingival debridement in subjects with periodontal pockets.
Methods: In a parallel design study, 79 periodontally diseased pocket sites were randomized to 3 groups: group 1 (n=25), scaling and root planing (SRP)+i-PRF+Cip; group 2 (n=25), SRP+i-PRF; group 3 (n=25), SRP without any adjunctive intervention. Clinical parameters (probing depth [PD], clinical attachment level [CAL], gingival index [GI], plaque index [PI]) and microbial quantification (relative quantification of levels of Aggregatibacter actinomycetemcomitans) were assessed from baseline to 6th and 12th weeks of follow-up.
Results: All the treatment groups showed significant improvements in the clinical and microbial parameters assessed. Group 1 showed significantly higher PD and GI reduction with CAL gain and decreased in relative levels of A. actinomycetemcomitans in the 12th week, followed by group 2 compared to group 3.
Conclusion: Thus, within the limits of this study, it can be concluded that i-PRF could be considered a potential LDD vehicle for the delivery of ciprofloxacin in periodontal pocket therapy.